ArticleOncotarget2014
Potential clinical implications of BRAF mutations in histiocytic proliferations.
Article in Oncotarget, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 88 citations in OpenAlex.
- Bone Involvement in Rosai-Dorfman Disease (RDD): a Case Report and Systematic Literature Review.Current rheumatology reports · 2017Pooled it
- Targeted Therapy With Vemurafenib in Brazilian Children With Refractory Langerhans Cell Histiocytosis: Two Case Reports and Review of Literature.Cancer reports (Hoboken, N.J.) · 2024Review
- Application of PD-L1 blockade in refractory histiocytic sarcoma: A case report.Molecular and clinical oncology · 2022Article
- Progressive destruction of jaws caused by the delayed treatment of Langerhans cell histiocytosis in a 2-year-old boy: A case report.Oral radiology · 2022Article
- Article
- Development of BRAFV600E-positive acute myeloid leukemia in a patient on long-term dabrafenib for multisystem LCH.Blood advances · 2022Article
- Frequency detection of BRAF V600E mutation in a cohort of pediatric langerhans cell histiocytosis patients by next-generation sequencing.Orphanet journal of rare diseases · 2021Article
- Case Report: Early Association of Vemurafenib to Standard Chemotherapy in Multisystem Langerhans Cell Histiocytosis in a Newborn: Taking a Chance for a Better Outcome?Frontiers in oncology · 2021Article
- Does CD1a Expression Influence T Cell Function in Patients With Langerhans Cell Histiocytosis?Frontiers in immunology · 2021Article
- Immune Microenvironment in Langerhans Cell Histiocytosis: Potential Prognostic Indicators.Frontiers in oncology · 2021Article
- Descriptive Analysis of Histiocytic and Dendritic Cell Neoplasms: A Single-Institution Experience.Yonsei medical journal · 2020Article
- Rosai-Dorfman Disease-Utility of 18F-FDG PET/CT for Initial Evaluation and Follow-up.Clinical nuclear medicine · 2020Article
- [Mandibular Langerhans cell histiocytosis: a case report].Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology · 2020Article
- Vemurafenib in Langerhans cell histiocytosis: report of a pediatric patient and review of the literature.Oncotarget · 2018Article
- Expression of enhancer of zeste homolog 2 (EZH2) protein in histiocytic and dendritic cell neoplasms with evidence for p-ERK1/2-related, but not MYC- or p-STAT3-related cell signaling.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2018Article
- The use of BRAF V600E mutation-specific immunohistochemistry in pediatric Langerhans cell histiocytosis.Hematological oncology · 2018Article
- Assessment of BRAFVirchows Archiv : an international journal of pathology · 2018Article
- Cytological findings of langerhans cell sarcoma in a case of quintuple cancer.Diagnostic cytopathology · 2017Article
- BRAFJournal of medical case reports · 2017Article
- Clinicopathological features and BRAFDiagnostic pathology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
For a growing number of tumors the BRAF V600E mutation carries therapeutic relevance. In histiocytic proliferations the distribution of BRAF mutations and their relevance has not been clarified. Here we present a retrospective genotyping study and a prospective observational study of a patient treated with a BRAF inhibitor. Genotyping of 69 histiocytic lesions revealed that 23/48 Langerhans cell lesions were BRAF-V600E-mutant whereas all non-Langerhans cell lesions (including dendritic cell sarcoma, juvenile xanthogranuloma, Rosai-Dorfman disease, and granular cell tumor) were wild-type. A metareview of 29 publications showed an overall mutation frequency of 48.5% and with N=653 samples this frequency is well defined. The BRAF mutation status cannot be predicted based on clinical parameters and outcome analysis showed no difference. Genotyping identified a 45 year-old woman with an aggressive and treatment-refractory, ultrastructurally confirmed systemic BRAF-mutant LCH. Prior treatments included glucocorticoid/vinblastine and cladribine-monotherapy. Treatment with vemurafenib over 3 months resulted in a dramatic metabolic response by FDG-PET and stable radiographic disease; the patient experienced progression after 6 months. In conclusion, BRAF mutations in histiocytic proliferations are restricted to lesions of the Langerhans-cell type. While for most LCH-patients efficient therapies are available, patients with BRAF mutations may benefit from the BRAF inhibitor vemurafenib.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.